Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone609-452-9813
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.06 million
Profitability
Miscellaneous
Employees58
Next Earnings Date1/9/2020 (Estimated)
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) announced its quarterly earnings data on Monday, September, 9th. The biotechnology company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.24) by $0.24. The biotechnology company had revenue of $0.01 million for the quarter. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
1 Wall Street analysts have issued 12-month target prices for Advaxis' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Advaxis' stock price to reach $4.00 in the next year. This suggests a possible upside of 1,039.3% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis.
Has Advaxis been receiving favorable news coverage?
Headlines about ADXS stock have been trending somewhat positive on Monday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Advaxis earned a news sentiment score of 0.8 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Advaxis.
Are investors shorting Advaxis?
Advaxis saw a decline in short interest in the month of September. As of September 15th, there was short interest totalling 235,600 shares, a decline of 61.7% from the August 15th total of 615,600 shares. Based on an average daily trading volume, of 1,880,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.0% of the company's shares are short sold. View Advaxis' Current Options Chain.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Ceapro (CRPOF), OncoSec Medical (ONCS), Mateon Therapeutics (MATN), Acerus Pharmaceuticals (TRLPF), ProPhase Labs (PRPH), Aytu Bioscience (AYTU), Aerpio Pharmaceuticals (ARPO), AEterna Zentaris (AEZS), Cassava Sciences (SAVA), Seelos Therapeutics (SEEL), AzurRx BioPharma (AZRX), RegeneRx Biopharmaceuticals (RGRX), Kazia Therapeutics (KZIA), BIOLINERX LTD/S (BLRX) and Evoke Pharma (EVOK).
What other stocks do shareholders of Advaxis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Celgene (CELG), Anavex Life Sciences (AVXL), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), ContraVir Pharmaceuticals (CTRV) and Novavax (NVAX).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
- Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
- Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.35.
How big of a company is Advaxis?
Advaxis has a market capitalization of $6.05 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
